Immunocore Hldgs
(NASDAQ:IMCR)
$54.93
-1.08[-1.93%]
Last update: 11:49AM Get Real Time Here
Consensus Rating1
Buy
Highest Price Target1
$100.00
Lowest Price Target1
$67.00
Consensus Price Target1
$76.94

Immunocore Hldgs Stock (NASDAQ:IMCR), Analyst Ratings, Price Targets, Predictions

Immunocore Holdings PLC has a consensus price target of $76.94, established from looking at the 53 latest analyst ratings. The last 3 analyst ratings were released from Mizuho, Canaccord Genuity, and HC Wainwright & Co. on May 13, 2024, May 9, 2024, and May 9, 2024. With an average price target of $85 between Mizuho, Canaccord Genuity, and HC Wainwright & Co., there's an implied 54.74% upside for Immunocore Holdings PLC from these 3 analyst ratings.

Analyst Trend
1
Nov 23
3
Feb
3
Mar
3
Apr
3
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Mizuho
Canaccord Genuity
HC Wainwright & Co.
Needham
Leerink Partners

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Immunocore Hldgs

Buy NowGet Alert
05/13/2024Buy Now60.2%Mizuho
Graig Suvannavejh
$90 → $88MaintainsBuyGet Alert
05/09/2024Buy Now21.97%Canaccord Genuity
Bill Maughan
$63 → $67MaintainsHoldGet Alert
05/09/2024Buy Now82.05%HC Wainwright & Co.
Patrick Trucchio
$90 → $100MaintainsBuyGet Alert
05/09/2024Buy Now47.46%Needham
Gil Blum
→ $81ReiteratesBuy → BuyGet Alert
04/29/2024Buy Now34.72%Leerink Partners
Jonathan Chang
→ $74Initiates → OutperformGet Alert
04/23/2024Buy Now67.49%Guggenheim
Michael Schmidt
→ $92ReiteratesBuy → BuyGet Alert
04/11/2024Buy Now47.46%Needham
Gil Blum
→ $81ReiteratesBuy → BuyGet Alert
03/20/2024Buy Now27.43%JP Morgan
Jessica Fye
$60 → $70MaintainsOverweightGet Alert
03/06/2024Buy Now63.84%HC Wainwright & Co.
Patrick Trucchio
→ $90ReiteratesBuy → BuyGet Alert
03/05/2024Buy Now63.84%Mizuho
Graig Suvannavejh
$86 → $90MaintainsBuyGet Alert
02/29/2024Buy Now58.38%Oppenheimer
Justin Kim
$85 → $87ReiteratesOutperform → OutperformGet Alert
02/29/2024Buy Now14.69%Canaccord Genuity
Bill Maughan
$60 → $63MaintainsHoldGet Alert
02/29/2024Buy Now47.46%Needham
Gil Blum
→ $81ReiteratesBuy → BuyGet Alert
02/16/2024Buy Now56.56%Mizuho
Graig Suvannavejh
$72 → $86MaintainsBuyGet Alert
11/20/2023Buy Now9.23%JP Morgan
Jessica Fye
→ $60Reinstates → OverweightGet Alert
11/02/2023Buy Now—Cantor Fitzgerald
Eric Schmidt
—Initiates → OverweightGet Alert
10/31/2023Buy Now52.92%Baird
Jack Allen
→ $84Initiates → OutperformGet Alert
09/21/2023Buy Now54.74%Oppenheimer
Justin Kim
$75 → $85MaintainsOutperformGet Alert
09/13/2023Buy Now36.54%Needham
Gil Blum
→ $75Initiates → BuyGet Alert
08/23/2023Buy Now63.84%HC Wainwright & Co.
Patrick Trucchio
→ $90ReiteratesBuy → BuyGet Alert
08/16/2023Buy Now52.92%Capital One
Naureen Quibria
→ $84Initiates → OverweightGet Alert
08/11/2023Buy Now65.67%BTIG
Justin Zelin
$85 → $91MaintainsBuyGet Alert
08/11/2023Buy Now36.54%Oppenheimer
Justin Kim
$72 → $75MaintainsOutperformGet Alert
08/11/2023Buy Now63.84%HC Wainwright & Co.
Patrick Trucchio
→ $90ReiteratesBuy → BuyGet Alert
08/01/2023Buy Now43.82%Morgan Stanley
Andrew Galler
$79 → $79ReiteratesOverweight → OverweightGet Alert
07/31/2023Buy Now43.82%Morgan Stanley
Andrew Galler
$79 → $79ReiteratesOverweight → OverweightGet Alert
07/24/2023Buy Now43.82%Morgan Stanley
Andrew Galler
$79 → $79ReiteratesOverweight → OverweightGet Alert
07/17/2023Buy Now43.82%Morgan Stanley
Andrew Galler
$79 → $79ReiteratesOverweight → OverweightGet Alert
07/17/2023Buy Now21.97%Canaccord Genuity
Bill Maughan
→ $67Initiates → HoldGet Alert
07/11/2023Buy Now43.82%Morgan Stanley
Andrew Galler
$79 → $79ReiteratesOverweight → OverweightGet Alert
06/26/2023Buy Now43.82%Morgan Stanley
Andrew Galler
$79 → $79ReiteratesOverweight → OverweightGet Alert
06/20/2023Buy Now43.82%Goldman Sachs
Rajan Sharma
→ $79Reiterates → OverweightGet Alert
06/12/2023Buy Now43.82%Morgan Stanley
Andrew Galler
→ $79Reiterates → OverweightGet Alert
05/12/2023Buy Now63.84%HC Wainwright & Co.
Patrick Trucchio
→ $90ReiteratesBuy → BuyGet Alert
05/11/2023Buy Now34.72%Mizuho
Graig Suvannavejh
$70 → $74MaintainsBuyGet Alert
05/09/2023Buy Now63.84%HC Wainwright & Co.
Patrick Trucchio
→ $90Reiterates → BuyGet Alert
04/19/2023Buy Now63.84%HC Wainwright & Co.
Patrick Trucchio
→ $90Reiterates → BuyGet Alert
03/31/2023Buy Now27.43%Mizuho
Graig Suvannavejh
→ $70Initiates → BuyGet Alert
03/30/2023Buy Now54.74%Guggenheim
Michael Schmidt
→ $85Initiates → BuyGet Alert
03/08/2023Buy Now63.84%HC Wainwright & Co.
Patrick Trucchio
→ $90Reiterates → BuyGet Alert
02/15/2023Buy Now31.08%Oppenheimer
Justin Kim
$65 → $72MaintainsOutperformGet Alert
12/16/2022Buy Now—Goldman Sachs
Rajan Sharma
—UpgradeNeutral → BuyGet Alert
11/30/2022Buy Now45.64%Barclays
Peter Lawson
→ $80Initiates → OverweightGet Alert
11/21/2022Buy Now63.84%HC Wainwright & Co.
Patrick Trucchio
$80 → $90MaintainsBuyGet Alert
11/10/2022Buy Now43.82%Morgan Stanley
Andrew Galler
$72 → $79MaintainsOverweightGet Alert
10/13/2022Buy Now31.08%Morgan Stanley
Andrew Galler
$77 → $72MaintainsOverweightGet Alert
09/14/2022Buy Now21.97%JP Morgan
Jessica Fye
$60 → $67MaintainsOverweightGet Alert
09/09/2022Buy Now40.18%Morgan Stanley
Andrew Galler
→ $77Initiates → OverweightGet Alert
09/08/2022Buy Now49.28%Ladenburg Thalmann
Ahu Demir
→ $82Initiates → BuyGet Alert
08/08/2022Buy Now27.43%Cowen & Co.
Tyler Van Buren
→ $70Initiates → OutperformGet Alert
08/02/2022Buy Now54.74%BTIG
Justin Zelin
→ $85Initiates → BuyGet Alert
02/08/2022Buy Now45.64%HC Wainwright & Co.
Patrick Trucchio
→ $80Initiates → BuyGet Alert
10/20/2021Buy Now1.95%Oppenheimer
Justin Kim
—Initiates → OutperformGet Alert

FAQ

Q

What is the target price for Immunocore Hldgs (IMCR)?

A

The latest price target for Immunocore Hldgs (NASDAQ: IMCR) was reported by Mizuho on May 13, 2024. The analyst firm set a price target for $88.00 expecting IMCR to rise to within 12 months (a possible 60.20% upside). 33 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Immunocore Hldgs (IMCR)?

A

The latest analyst rating for Immunocore Hldgs (NASDAQ: IMCR) was provided by Mizuho, and Immunocore Hldgs maintained their buy rating.

Q

When was the last upgrade for Immunocore Hldgs (IMCR)?

A

The last upgrade for Immunocore Holdings PLC happened on December 16, 2022 when Goldman Sachs raised their price target to N/A. Goldman Sachs previously had a neutral for Immunocore Holdings PLC.

Q

When was the last downgrade for Immunocore Hldgs (IMCR)?

A

There is no last downgrade for Immunocore Hldgs.

Q

When is the next analyst rating going to be posted or updated for Immunocore Hldgs (IMCR)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunocore Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunocore Hldgs was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.

Q

Is the Analyst Rating Immunocore Hldgs (IMCR) correct?

A

While ratings are subjective and will change, the latest Immunocore Hldgs (IMCR) rating was a maintained with a price target of $90.00 to $88.00. The current price Immunocore Hldgs (IMCR) is trading at is $54.93, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch